Clinical Trial Update: Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability update for Lu AF35700 in schizophrenia patients following repeated dosing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Lu AF35700 (Lu AF35700)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED